NextCure shareholders elect directors, approve amended equity plan with 80,000 additional shares

NextCure, Inc.

Anne Borgman, M.D. and John G. Houston, Ph.D. reelected as Class I directors for 3-year terms.
Shareholders approved amendment and restatement of 2019 Omnibus Incentive Plan, increasing authorized shares by 80,000.
Ratification of Ernst & Young LLP as independent auditor for fiscal 2026 passed with 2,774,832 votes for.
Advisory vote on executive compensation passed with 2,109,269 votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.